Aducanumab tops 2021’s biggest potential launches
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Holding a contingent value right in uncertain times
Though the stage is apparently set for Bristol’s contingent value right to pay out, the instrument trades at depressed levels.
FDA keeps the faith in surrogate endpoints
The US regulator granted 14 accelerated approvals in 2019, fewer than in the previous two years, and the sector remains slow at conversions.
Upcoming events – Vertex awaits triplet data and GBT seeks approval for approval
Vertex is due the first pivotal data on its cystic fibrosis triplets, while Global Blood Therapeutics will soon find out whether it can take a shortcut on voxelotor’s…
Pharma’s fastest followers revealed
Analysis of me-too drug approvals over time shows trends across therapy areas.
Upcoming events – FDA decisions loom for Alnylam and Pfizer
The companies hope that the US regulator approves patisiran and lorlatinib.
Roche tries again with a new pill for flu
A new influenza antiviral from Roche and Shionogi could become an important new medicine for both groups, if payers can be convinced.
